Influenza A Market: Epidemiology, Therapies, Companies, DelveInsight | Cidara Therapeutics, SAb Biotherapeutics, FluGen, Moderna, Vir Biotechnology, Vaxart

Influenza A therapies, such as XOFLUZA, RAPIVAB, FLUAD QUADRIVALENT, mRNA-1010, CD388, Flu Pandemic mRNA (GSK4382276A), CC-42344, and others, are expected to boost the Influenza A Market in the upcoming years.

DelveInsight has launched a new report on "Influenza A - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Influenza A, historical and forecasted epidemiology as well as the Influenza A market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover about the Influenza A market report @ https://www.delveinsight.com/report-store/influenza-a-infections-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Some of the key facts of the Influenza A Market Report:

Leading companies in the Influenza A space include **Roche**, **BioCryst Pharmaceuticals**, **Seqirus**, **Moderna**, **Cidara Therapeutics**, **GlaxoSmithKline**, **Cocrystal Pharma**, and others.
The development pipeline for Influenza A showcases several promising mid- to late-stage candidates-both **drugs and vaccines**-such as **mRNA-1010**, **CD388**, **Flu Pandemic mRNA (GSK4382276A)**, **CC-42344**, and more.
In September 2024, the FDA approved AstraZeneca's FluMist for self-administration, making it the first influenza vaccine that doesn't require a healthcare provider for administration. This nasal spray vaccine is suitable for individuals aged 2 to 49 years and aims to enhance convenience and accessibility for seasonal flu prevention.
The FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) convened in March 2024 to recommend the composition of influenza vaccines for the 2024-2025 U.S. influenza season. These recommendations are based on global surveillance data to ensure the vaccines effectively target the most prevalent strains.
The vaccinated population for Influenza A is segmented by age groups, including children (0-4 and 5-12 years), adolescents (13-17 years), adults (18-49, 50-64, and 65+ years), and pregnant women. In 2024, the highest vaccination coverage in the U.S. was observed in adults aged 18-49, while the lowest was among pregnant women. Despite these efforts, the estimated vaccine failure rate in the U.S. was approximately 70% in 2024.
In Japan, data from the Ministry of Health, Labour and Welfare indicated that the average number of influenza A cases per medical institution in 2024 reached 64.39-exceeding the previous high of 57.09 recorded in January 2019. Meanwhile, the European Respiratory Virus Surveillance Summary (ERVISS, 2025) reported that the H1N1 pdm09 subtype accounted for the majority (57%-93%) of circulating influenza A cases across Europe in 2024.
This emerging pipeline signals improved treatment prospects for Influenza A, with advancements in **early diagnosis** and **heightened public awareness** playing a critical role in enhancing outcomes.
Promising Influenza A therapies include XOFLUZA, RAPIVAB, FLUAD QUADRIVALENT, mRNA-1010, CD388, Flu Pandemic mRNA (GSK4382276A), CC-42344, and others.

Influenza A Overview

Influenza A viruses are classified into subtypes based on two surface proteins: **hemagglutinin (H)** and **neuraminidase (N)**, with 18 H and 11 N types identified, resulting in over 130 known combinations-mostly found in wild birds. The **currently circulating H1N1 strain** traces back to the 2009 pandemic and has since evolved genetically and antigenically. Occasionally, a major transformation known as **antigenic shift** occurs, leading to new subtypes that can spark global pandemics due to the lack of immunity in the population.

**Symptoms** of Influenza A range from mild (fever, cough, fatigue, sore throat) to severe (pneumonia, sepsis, breathing difficulties). Elderly individuals and those with preexisting health conditions are at a higher risk of serious complications.

Influenza A Market Outlook

Influenza A vaccines, updated annually based on global surveillance, are critical for preventing infection and reducing illness severity. Notable vaccines like FLUZONE (inactivated) and FluMist (live attenuated) help generate protective antibodies, especially benefiting high-risk groups such as the elderly and those with chronic conditions.

In addition to vaccines, antiviral drugs like TAMIFLU, RELENZA, RAPIVAB, and XOFLUZA are essential for managing infections. When given early, they can shorten the illness by about a day and lower the risk of complications like pneumonia, particularly in vulnerable individuals.

Despite advancements in vaccines and treatments, influenza A remains a challenge due to its constant mutation through antigenic drift and shift. Continued efforts are needed to address persistent gaps and enhance disease understanding.

Discover how the Influenza A market is rising in the coming years @ https://www.delveinsight.com/sample-request/influenza-a-infections-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Influenza A Marketed Drugs

XOFLUZA (baloxavir marboxil): Roche and Shionogi
RAPIVAB (peramivir): BioCryst Pharmaceuticals

Influenza A Emerging Drugs
CC-42344: Cocrystal Pharma
CD388: Cidara Therapeutics

Scope of the Influenza A Market Report
Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Influenza A Companies: Cidara Therapeutics, SAb Biotherapeutics, FluGen, Moderna, Vir Biotechnology, Vaxart, and others
Key Influenza A Therapies: XOFLUZA, RAPIVAB, FLUAD QUADRIVALENT, mRNA-1010, CD388, Flu Pandemic mRNA (GSK4382276A), CC-42344, and others
Influenza A Therapeutic Assessment: Influenza A current marketed and Influenza A emerging therapies
Influenza A Market Dynamics: Influenza A market drivers and Influenza A market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Influenza A Unmet Needs, KOL's views, Analyst's views, Influenza A Market Access and Reimbursement

To know what's more in our Influenza A report, visit https://www.delveinsight.com/report-store/influenza-a-infections-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key benefits of the Influenza A Market Report:
Influenza A market report covers a descriptive overview and comprehensive insight of the Influenza A Epidemiology and Influenza A market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).
The Influenza A market report provides insights into the current and emerging therapies.
The Influenza A market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Influenza A market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Influenza A market.

Got queries? Click here to know more about the Influenza A market Landscape https://www.delveinsight.com/sample-request/influenza-a-infections-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents

1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Influenza A Patient Share (%) Overview at a Glance
5. Influenza A Market Overview at a Glance
6. Influenza A Disease Background and Overview
7. Influenza A Epidemiology and Patient Population
8. Country-Specific Patient Population of Influenza A
9. Influenza A Current Treatment and Medical Practices
10. Unmet Needs
11. Influenza A Emerging Therapies
12. Influenza A Market Outlook
13. Country-Wise Influenza A Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Influenza A Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Click here to read more about Influenza A Market Outlook 2034 https://www.delveinsight.com/report-store/influenza-a-infections-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Related Reports:

Influenza A Pipeline Insights, DelveInsight

"Influenza A Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Influenza A market. A detailed picture of the Influenza A pipeline landscape is provided, which includes the disease overview and Influenza A treatment guidelines.

Contact Info:

Kritika Rehani, Assistant Manager, Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.